Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-10-25 4:23 pm Sale | 2024-09-30 | 13G | Protalix BioTherapeutics, Inc. PLX | WHITEBOX ADVISORS LLC | 0 0.000% | -2,816,108 (Position Closed) | Filing History |
| 2024-01-02 06:36 am Sale | 2023-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX | NACHT MARIUS | 2,208,913 2.900% | -607,988 (-21.58%) | Filing History |
| 2023-01-03 06:01 am Unchanged | 2022-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX | NACHT MARIUS | 2,816,901 5.300% | 0 (Unchanged) | Filing History |
| 2022-06-09 2:52 pm Purchase | 2022-05-13 | 13G | Protalix BioTherapeutics, Inc. PLX | WHITEBOX ADVISORS LLC | 2,816,108 5.650% | 2,816,108 (New Position) | Filing History |
| 2022-02-14 3:14 pm Purchase | 2021-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX | HIGHBRIDGE CAPITAL MANAGEMENT LLC | 2,414,487 5.030% | 2,414,487 (New Position) | Filing History |
| 2022-02-11 08:19 am Sale | 2021-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX | HIGHBRIDGE CAPITAL MANAGEMENT LLC | 0 0.000% | -6,063,194 (Position Closed) | Filing History |
| 2022-01-31 07:16 am Sale | 2021-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX | NACHT MARIUS | 2,816,901 5.800% | -570,421 (-16.84%) | Filing History |
| 2021-07-30 06:02 am Sale | 2021-06-30 | 13G | Protalix BioTherapeutics, Inc. PLX | BURRAGE CAPITAL MANAGEMENT LLC | 0 0.000% | -2,470,332 (Position Closed) | Filing History |
| 2021-06-15 09:19 am Sale | 2021-06-14 | 13G | Protalix BioTherapeutics, Inc. PLX | Dexcel Pharma Technologies Ltd. | 2,034,117 4.470% | -2,521,914 (-55.35%) | Filing History |
| 2021-02-16 12:06 pm Purchase | 2021-02-12 | 13G | Protalix BioTherapeutics, Inc. PLX | Dexcel Pharma Technologies Ltd. | 4,556,031 10.300% | 1,267,940 (+38.56%) | Filing History |
| 2021-02-16 10:03 am Purchase | 2020-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX | OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,091,176 3.200% | 150,000 (+15.94%) | Filing History |
| 2021-02-12 12:00 pm Purchase | 2020-12-04 | 13G | Protalix BioTherapeutics, Inc. PLX | BURRAGE CAPITAL MANAGEMENT LLC | 2,470,332 7.410% | 2,470,332 (New Position) | Filing History |
| 2021-02-09 08:19 am Purchase | 2020-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX | HIGHBRIDGE CAPITAL MANAGEMENT LLC | 6,063,194 9.990% | 2,730,440 (+81.93%) | Filing History |
| 2021-02-08 11:51 am Unchanged | 2020-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX | CITIGROUP INC C | 921,412 2.700% | 0 (Unchanged) | Filing History |
| 2021-02-08 06:08 am Purchase | 2020-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX | NACHT MARIUS | 3,387,322 9.990% | 99,231 (+3.02%) | Filing History |